Feltgen, Nicolas

[["dc.bibliographiccitation.artnumber","e000182"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Open Heart"],["dc.bibliographiccitation.volume","2"],["dc.contributor.author","Seegers, Joachim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Grüter, Timo"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Weber-Krüger, Mark"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Gelbrich, Götz"],["dc.contributor.author","Binder, Lutz"],["dc.contributor.author","Herrmann-Lingen, Christoph"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2017-09-07T11:52:34Z"],["dc.date.available","2017-09-07T11:52:34Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1136/openhrt-2014-000182"],["dc.identifier.gro","3144967"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13598"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2650"],["dc.notes.intern","Crossref Import"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","public"],["dc.relation.issn","2053-3624"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Natriuretic peptides for the detection of paroxysmal atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1207"],["dc.bibliographiccitation.journal","Clinical Ophthalmology"],["dc.bibliographiccitation.lastpage","1213"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Zinser, Greta"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Nguyen-Höhl, Anna"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Gollisch, Katja"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.date.accessioned","2022-05-02T08:09:30Z"],["dc.date.available","2022-05-02T08:09:30Z"],["dc.date.issued","2022"],["dc.description.abstract","Purpose: To correlate functional and morphological parameters with foveal avascular zone’s (FAZ) size in diabetic patients with mild to moderate stage nonproliferative diabetic retinopathy. Methods: Monocentric and prospective study of a consecutive case series of diabetic patients. Medical history, best corrected visual acuity (BCVA), best corrected high/low contrast visual acuity (BChcVA/BClcVA), mean sensitivity (MS) and mean defect (MD) in central visual field testing, and FAZ size in fluorescein-angiography (FAG) were recorded. Macular thickness (central point thickness CPT, central subfield thickness CST) and volume measurements (central subfield volume CSV, total macular volume) were taken from SD-OCT (6x6mm ETDRS-grid). Groups were categorised as presenting FAZ sizes smaller (G1) or larger (G2) than 0.35mm2 . Smallest (Q1) and largest quartiles (Q3) were also compared. Results: Thirty-six of 40 patients were included. MS differed significantly between G1 (n = 6) and G2 (n = 30), and BChcVA/BClcVA as well as TMV correlated significantly with FAZ size in correlation analysis. Mean HbA1c tended to be lower in G1 than G2. Patients in G1 were slightly older than in G2. Treatment period with insulin was shorter in G1/Q1 than in G2/Q3. CPT and TMV were lower in G1/Q1 than in G2/Q3. Our analysis of the FAZ in terms of patient age, HbA1c, disease duration and insulin therapy duration revealed no significance. That lack of significance also applies to BCVA, MS, MD, CPT, CST and CSV. Conclusion: As significantly associated, contrast sensitivity, central visual field parameters and potentially retinal thickness or volume seem to be suitable to detect early macular ischaemia. However, we failed to establish any correlation between FAZ and BCVA"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.2147/OPTH.S358467"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107396"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-561"],["dc.relation.eissn","1177-5483"],["dc.rights","CC BY-NC 3.0"],["dc.title","Influence of the Size of the Foveal Avascular Zone on Functional and Morphological Parameters in Patients with Early-Stage Diabetic Retinopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","7"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Ophthalmology"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Ziemssen, F."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Holz, FG."],["dc.contributor.author","Guthoff, R."],["dc.contributor.author","Ringwald, A."],["dc.contributor.author","Bertelmann, T."],["dc.contributor.author","Wiedon, A."],["dc.contributor.author","Korb, C."],["dc.date.accessioned","2019-07-09T11:43:05Z"],["dc.date.available","2019-07-09T11:43:05Z"],["dc.date.issued","2017"],["dc.description.abstract","Abstract Background While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. Methods The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO). Baseline patient characteristics were compared by indication within the OCEAN cohort. Furthermore, the characteristics were set in reference to those of published RCTs in the same indications. Confidence intervals (CIs) were calculated and assessed for statistically significant differences as indicated by non-overlapping CIs. Results Patient characteristics in the NIS OCEAN were evaluated for 3,614 patients with nAMD, 1,211 with DME, 204 with BRVO and 121 with CRVO. Between these groups, significant differences in mean age, gender distributions, and mean baseline VA were seen, reflecting known differences between the indications. Compared to the patient characteristics of published RCTs (trials selected by literature search: nAMD: 13 RCTs, DME: 9, RVO: 5), the OCEAN patients’ mean age was significantly higher in every indication. The gender distributions across the trials were comparable, with only few differences between OCEAN and the RCTs. Regarding the mean baseline VA, notable differences were found in nAMD and in DME, with VA significantly higher in some RCTs and lower in others. Conclusions The described differences underline the complementarity of NISs and RCTs. OCEAN covers a broader spectrum and more variability of patients than do RCTs. As baseline values may have impact on the treatment response (ceiling effect), there is an ongoing need for research in all patient subgroups. Country-specific assessments of patient populations can better reflect the real-world situation. NISs can deliver insights that RCTs may not, as NISs can include non-typical patients, patients with comorbidities, a broader age spectrum and patients of various disease stages. Trial registration The NIS OCEAN was registered on www.clinicaltrials.gov (identifier: NCT02194803 )."],["dc.identifier.doi","10.1186/s12886-017-0401-y"],["dc.identifier.pmid","28103831"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58822"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","100031"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Ophthalmology Science"],["dc.bibliographiccitation.volume","1"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Heins, Amelie"],["dc.contributor.author","Lauermann, Peer"],["dc.contributor.author","Storch, Marcus Werner"],["dc.contributor.author","Khattab, Mohammed Haitham"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","van Oterendorp, Christian"],["dc.date.accessioned","2022-05-13T06:27:45Z"],["dc.date.available","2022-05-13T06:27:45Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1016/j.xops.2021.100031"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/107850"],["dc.language.iso","en"],["dc.relation.issn","2666-9145"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","Reliability of Subjective Assessment of Spectral-Domain OCT Pathologic Features by Multiple Raters in Retinal Vein Occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","8"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Ophthalmologica"],["dc.bibliographiccitation.lastpage","17"],["dc.bibliographiccitation.volume","233"],["dc.contributor.author","Kreutzer, Thomas C."],["dc.contributor.author","Wolf, Armin"],["dc.contributor.author","Dirisamer, Martin"],["dc.contributor.author","Strauss, Rupert W."],["dc.contributor.author","Foerster, Paul"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Hattenbach, Lars-Olof"],["dc.contributor.author","Kampik, Anselm"],["dc.contributor.author","Priglinger, Siegfried G."],["dc.contributor.author","Pielen, Amelie"],["dc.date.accessioned","2018-11-07T10:03:46Z"],["dc.date.available","2018-11-07T10:03:46Z"],["dc.date.issued","2015"],["dc.description.abstract","Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (+/- 19.3) letters compared to +25.2 (+/- 20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI. (C) 2014 S. Karger AG, Basel"],["dc.description.sponsorship","Novartis Pharma GmbH, Nuremberg, Germany"],["dc.identifier.doi","10.1159/000369566"],["dc.identifier.isi","000348968800003"],["dc.identifier.pmid","25502833"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38546"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0267"],["dc.relation.issn","1423-0267"],["dc.relation.issn","0030-3755"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","338"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Schnieder, Marlena"],["dc.contributor.author","Fischer-Wedi, Charlotte V."],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Kortleben, Mai-Linh"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Liman, Jan"],["dc.date.accessioned","2021-04-14T08:29:40Z"],["dc.date.available","2021-04-14T08:29:40Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.3390/jcm10020338"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82962"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","The Retrobulbar Spot Sign and Prominent Middle Limiting Membrane as Prognostic Markers in Non-Arteritic Retinal Artery Occlusion"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","aos.14940"],["dc.bibliographiccitation.firstpage","295"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Acta Ophthalmologica"],["dc.bibliographiccitation.lastpage","301"],["dc.bibliographiccitation.volume","100"],["dc.contributor.affiliation","Gebler, Marie; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Pfeiffer, Sebastian; 2\r\nDepartment of Research, Teaching and Clinical Science University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Callizo, Josep; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Hoerauf, Hans; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.affiliation","Feltgen, Nicolas; 1\r\nDepartment of Ophthalmology University Medical Center Goettingen Goettingen Germany"],["dc.contributor.author","Gebler, Marie"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2021-07-05T14:57:41Z"],["dc.date.available","2021-07-05T14:57:41Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T21:23:28Z"],["dc.description.abstract","Abstract Purpose To assess the incidence of cystoid macular oedema (CME) diagnosed by spectral domain optical coherence tomography (SD‐OCT) after primary rhegmatogenous retinal detachment (RRD) surgery. Methods From April 2016 to October 2017, 150 eyes of 150 patients presenting with primary RRD were included consecutively in this prospective single‐centre study. Patients with the following characteristics were excluded: previous vitreoretinal surgery, combined cataract surgery, preoperatively presentation with any intraocular or systemic inflammatory condition, visible macular oedema or epiretinal membrane (ERM) on funduscopy. SD‐OCT (Spectralis, Heidelberg Engineering) was conducted 3 and 6 weeks after surgery. Results One hundred and twenty‐eight of the 150 patients completed the study, of whom 107 (age: 61.7 ± 11.5 years, mean ± SD) showed successful retinal attachment during follow‐up visits. The most frequent operation method was scleral buckling (54.2%), followed by vitrectomy (25.2%) and the combination of both techniques (20.6%). Postoperative SD‐OCT revealed CME, neurosensory detachment and ERM in 18.7, 31.8 and 32.7% of all cases, respectively. The risk of postoperative CME was significantly elevated in patients with ERM (42.9 versus 6.9%, p < 0.001). In addition, patients with initial detachment of the macula had more postoperative CME (26.5 versus 11.1%, p = 0.044). BCVA improvement was significantly lower in patients with CME compared to patients without 6 weeks after surgery for macula‐on RRD. Conclusions This prospective study confirmed that postoperative CME is a frequent complication after RRD surgery; we identified ERM and macula‐off RRD as potential risk factors. As CME potentially delays visual recovery, postoperative follow‐ups should include SD‐OCT."],["dc.identifier.doi","10.1111/aos.14940"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87706"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1755-3768"],["dc.relation.issn","1755-375X"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Incidence and risk factors for macular oedema after primary rhegmatogenous retinal detachment surgery: a prospective single‐centre study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e78538"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Pielen, Amelie"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Isserstedt, Christin"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Junker, Bernd"],["dc.contributor.author","Schmucker, Christine"],["dc.date.accessioned","2018-11-07T09:18:29Z"],["dc.date.available","2018-11-07T09:18:29Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: Intravitreal agents have replaced observation in macular edema in central (CRVO) and grid laser photocoagulation in branch retinal vein occlusion (BRVO). We conducted a systematic review to evaluate efficacy and safety outcomes of intravitreal therapies for macular edema in CRVO and BRVO. Methods: And Findings: MEDLINE, Embase, and the Cochrane Library were systematically searched for RCTs with no limitations of language and year of publication. 11 RCTs investigating anti-VEGF agents (ranibizumab, bevacizumab, aflibercept) and steroids (triamcinolone, dexamethasone implant) with a minimum follow-up of 1 year were evaluated. Efficacy: CRVO: Greatest gain in visual acuity after 12 months was observed both under aflibercept 2 mg: +16.2 letters (8.5 injections), and under bevacizumab 1.25 mg: +16.1 letters (8 injections). Ranibizumab 0.5 mg improved vision by +13.9 letters (8.8 injections). Triamcinolone 1 mg and 4 mg stabilized visual acuity at a lower injection frequency (-1.2 letters, 2 injections). BRVO: Ranibizumab 0.5 mg resulted in a visual acuity gain of +18.3 letters (8.4 injections). The effect of dexamethasone implant was transient after 1.9 implants in both indications. Safety: Serious ocular adverse events were rare, e. g., endophthalmitis occurred in 0.0-0.9%. Major differences were found in an indirect comparison between steroids and anti-VEGF agents for cataract progression (19.8-35.0% vs. 0.9-7.0%) and in required treatment of increased intraocular pressure (7.0-41.0% vs. none). No major differences were identified in systemic adverse events. Conclusions: Anti-VEGF agents result in a promising gain of visual acuity, but require a high injection frequency. Dexamethasone implant might be an alternative, but comparison is impaired as the effect is temporary and it has not yet been tested in PRN regimen. The ocular risk profile seems to be favorable for anti-VEGF agents in comparison to steroids. Because comparative data from head-to-head trials are missing currently, clinicians and patients should carefully weigh the benefit-harm ratio."],["dc.identifier.doi","10.1371/journal.pone.0078538"],["dc.identifier.isi","000326155400083"],["dc.identifier.pmid","24205253"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10754"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28422"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","132"],["dc.bibliographiccitation.journal","Health and Quality of Life Outcomes"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Scheffler, Martin"],["dc.contributor.author","Hufenbach, Ulrich"],["dc.contributor.author","Wiedon, Annette"],["dc.contributor.author","Wilhelm, Helmut"],["dc.contributor.author","Ziemssen, Focke"],["dc.date.accessioned","2018-11-07T10:08:27Z"],["dc.date.available","2018-11-07T10:08:27Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in ophthalmological clinical research. However, to date only little information is available about vrQoL from large non-interventional studies in terms of \"real-world evidence\". The purpose of this investigation was to describe baseline VFQ-25 visual function scores, to evaluate whether they differ from previous phase III clinical trials, to determine which contributing factors (e.g. indication, age, gender) affect VFQ-25 scores and to identify its impact on driving. Methods: The non-interventional OCEAN study (Observation of treatment patterns with LuCEntis and real life ophthalmic monitoring, including optional OCT in Approved iNdications) is the largest ophthalmic study conducted in Germany, to evaluate the real world situation of patients treated with ranibizumab (NCT02194803). The NEI-VFQ-25 questionnaire was conducted at baseline, months 4, 12 and 24. Descriptive statistics was used to analyse the baseline data. ANOVA was performed to evaluate the impact of various contributing factors on composite and selected subscale scores. Results: Overall, 4844 (84.1 %) of all 5760 OCEAN patients completed the VFQ-25 questionnaire at baseline. Thereof, 3414 treatment-naive patients were further analysed. Overall, the VFQ subscore general health was most affected by the ocular disease, followed by general vision. No major differences were detected in comparison to corresponding VFQ-25 scores of previous phase III clinical trials, except in DME patients, or with respect to possible contributing factors. A tendency towards a more decreased VFQ-25 composite score was observed for nAMD, for elderly patients >= 75 years of age, for female patients, for patients with low baseline visual acuity (VA; <50 letters) and for those with statutory health insurance. Indication, age, gender, baseline VA (all p <0.01) and the interaction of age and indication, as well as baseline VA and indication (p <0.01 each) had a significant impact on composite, general vision and distance vision scores (ANOVA). About 10 % of patients gave up driving due to eyesight issues. Conclusions: The knowledge of a patient's subjective disease burden is crucial to understanding anxieties and mental anguish. Additionally, the understanding of the impact of various contributing factors on the VFQ-25 scores and the extent to which they can be influenced help to optimize patient care. It demonstrates the need for medical and mental support by all medical staff, to encourage patients' compliance with a comprehensive anti-VEGF therapy, to increase BCVA and, consecutively, VFQ-25 scores."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1186/s12955-016-0536-1"],["dc.identifier.isi","000384693800001"],["dc.identifier.pmid","27644469"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13885"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39464"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7525"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3097"],["dc.bibliographiccitation.issue","20"],["dc.bibliographiccitation.journal","FEBS letters"],["dc.bibliographiccitation.lastpage","3102"],["dc.bibliographiccitation.volume","582"],["dc.contributor.author","Stahl, A."],["dc.contributor.author","Paschek, L."],["dc.contributor.author","Martin, G."],["dc.contributor.author","Gross, N. J."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Hansen, L. L."],["dc.contributor.author","Agostini, H. T."],["dc.date.accessioned","2019-07-09T11:52:59Z"],["dc.date.available","2019-07-09T11:52:59Z"],["dc.date.issued","2008"],["dc.description.abstract","Anti-VEGF treatment has become accepted first-line treatment for choroidal neovascularisation (CNV) in age-related macular degeneration. However, VEGF-inhibition does not always lead to sustained CNV-reduction. In this study, the effect of rapamycin was superior to VEGF-inhibition in a co-culture assay of endothelial cells (ECs) and retinal pigment epithelium (RPE). Rapamycin reduced EC sprouting in groups that did not respond to anti-VEGF treatment. Rapamycin did not induce EC apoptosis, but reduced both VEGF-production in RPE and the responsiveness of ECs to stimulation. Rapamycin might therefore be a therapeutic option for CNV patients that do not respond sufficiently to the established anti-VEGF treatments."],["dc.identifier.doi","10.1016/j.febslet.2008.08.005"],["dc.identifier.pmid","18703055"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6261"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60313"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","0014-5793"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.subject.mesh","Angiogenesis Inhibitors"],["dc.subject.mesh","Apoptosis"],["dc.subject.mesh","Cells, Cultured"],["dc.subject.mesh","Choroidal Neovascularization"],["dc.subject.mesh","Coculture Techniques"],["dc.subject.mesh","Humans"],["dc.subject.mesh","Pigment Epithelium of Eye"],["dc.subject.mesh","Sirolimus"],["dc.subject.mesh","Vascular Endothelial Growth Factor A"],["dc.title","Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]